This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
This source states clearly that the drug is being developed by "Dana-Farber Cancer Institute; Massachusetts General Hospital; VBL Therapeutics". Why is only the last mentioned in the article? You should mention all or none, I think. Justlettersandnumbers (talk) 21:42, 23 February 2017 (UTC)[reply]
The drug itself was developed by VBL. Dana-Farber (which is associated with Mass Gen) is being used to host clinical trials and further testing of the drug. Natureium (talk) 15:26, 24 February 2017 (UTC)[reply]
From the first sentence: "VBL Therapeutics (also known as Vascular Biogenics) is developing ofranergene obadenovec, an intravenously administered dual-action, anti-angiogenic and vascular disrupting agent (VDA), for the treatment of solid tumours." and the table further down the page: "VBL Therapeutics, Owner, Israel; Dana-Farber Cancer Institute, Collaborator, USA; Massachusetts General Hospital, Collaborator, USA" Natureium (talk) 15:50, 24 February 2017 (UTC)[reply]
yep, the drug is owned by VBL and is being developed by them at various sites. adis lists clinical trial sites. Dana Farber is one of them. Jytdog (talk) 19:56, 29 August 2017 (UTC)[reply]